Title: VACCELERATE - The  New European Vaccine Research Network

Design: Phase  2 & 3 COVID-19 vaccine clinical trials

Registration  Number:  n.a.

Primary  Objective: VACCELERATE will be established as the network for pandemic preparedness in Europe. The goal is to plan and coordinate phase 2 & 3 vaccine trials in all  EU-member states and EU-associated countries under one  strategic-scientific umbrella. It  will serve as single-entry point for all stakeholders involved in COVID-19 vaccine development (pharma, academia, European Commission, EMA, ECDC, national health authorities and others).

Secondary  Objective(s):

• To address any research question outside the big registration trials, such as vaccine efficacy in case of virus variants, trials in children, pregnant women and immuno- compromised patients, trials on combination of different vaccines etc.

• Creation of a Stakeholder Working Group (SWG) to facilitate strategic discussions and to identify unanswered public health needs.

• Promotion  of a harmonised  acquisition, open exchange and consolidation of data for enhanced data analysis across trial through  the setting up of volunteer registries.

Additionally, VACCELERATE will address vaccine hesitancy through systematic reviews of available  information and through specific information material to dispel myths about vaccines and clinical trials.

Interested in a collaboration? Contact: Anna Maria Azzini annamaria.azzini@univr.it

Website: https://vaccelerate.eu/

Linkedin: https://www.linkedin.com/company/vaccelerate-eu/?viewAsMember=true

YouTube Channel: https://www.youtube.com/channel/UC1Gv0HDBdyG2Kk2UNo2HNDg